cancers

MDPI

Article

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

Victoria G. Atkinson [1,*], Pietro Quaglino [2], Massimo Aglietta [3], Michele Del Vecchio [4], Roberta Depenni [5], Francesca Consoli [6], Dimitrios Bafaloukos [7], Pier Francesco Ferrucci [8], Skaiste Tulyte [9], Ivana Krajsová [10], Paolo A. Ascierto [11], Rossana Gueli [12], Ana Arance [13], Helen Gogas [14], Hiya Banerjee [15], Teddy Saliba [15], Egbert de Jong [16], and Bart Neyns [17]

1 Division of Cancer Services, Princess Alexandra Hospital, University of Queensland, Brisbane QLD 4102, Australia
2 Department of Medical Sciences, Section of Dermatology, University of Turin, 10124 Turin, Italy; pietro.quaglino@unito.it
3 Candiolo Cancer Institute FPO-IRCCS, Candiolo, Department of Oncology, University of Torino, 10124 Turin, Italy; massimo.aglietta@ircc.it
4 Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; Michele.DelVecchio@istitutotumori.mi.it
5 Department of Oncology and Hematology, University of Modena and Reggio Emilia, 41121 Modena, Italy; depenni.roberta@policlinico.mo.it
6 Medical Oncology, ASST Spedali Civili, 25123 Brescia, Italy; francesca.consoli@libero.it
7 Medical Oncology, Metropolitan Hospital, 18547 Athens, Greece; dimmp@otenet.gr
8 Tumor Biotherapy Unit, Department of Experimental Oncology, IEO—Istituto Europeo di Oncologia—IRCCS, 20141 Milan, Italy; pier.ferrucci@ieo.it
9 Hematology, Oncology and Transfusion Medicine Center, Vilnius University, 08410 Vilnius, Lithuania; skaiste.tulyte@santa.lt
10 Department of Dermatovenerology, University Hospital Prague, Charles University, 12808 Prague, Czech Republic; ivana.krajsova@vfn.cz
11 Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori-IRCCS "Fondazione G. Pascale" 80131 Naples, Italy; paolo.ascierto@gmail.com
12 Oncology Unit, ASST Sette Laghi, 21100 Varese, Italy; rossana.gueli@asst-settelaghi.it
13 Department of Medical Oncology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain; amarance@clinic.cat
14 Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, 11527 Athens, Greece; helgogas@gmail.com
15 Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA; hiya.banerjee@novartis.com (H.B.); teddy.saliba@novartis.com (T.S.)
16 Novartis AG, 4057 Basel, Switzerland; egbert.de_jong@novartis.com
17 Medical Oncology, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium; Bart.Neyns@uzbrussel.be
* Correspondence: victoria.atkinson@health.qld.gov.au



Figure S1. (**A**) PFS and (**B**) OS in patients in the long-term, intermediate, and short-term duration of benefit groups. CI, confidence interval; mOS, median overall survival; mPFS, median progression-free survival; OS, overall survival; PFS, progression-free survival.

Table S1. On-treatment deaths.

Primary reason for death, *n* (%)	**Long-term Duration of Benefit, ≥12 months (*n* = 225)**	**Intermediate Duration of Benefit, ≥6 mo and <12 months (*n* = 139)**	**Short-term Duration of Benefit, <6 months (*n* = 145)**	**Overall (*N* = 509)**
On-treatment deaths	32 (14.2)	39 (28.1)	56 (38.6)	127 (25.0)
Melanoma	24 (10.7)	32 (23.0)	49 (33.8)	105 (20.6)
Other	8 (3.6)	7 (5.0)	7 (4.8)	22 (4.3)
Disease progression	5 (2.2)	4 (2.9)	3 (2.1)	12 (2.4)
Unknown	1 (0.4)	1 (0.7)	0	2 (0.4)
Neoplasm progression	0	1 (0.7)	1 (0.7)	2 (0.4)
Adverse event	1 (0.4)	0	0	1 (0.2)
Pneumonia	1 (0.4)	0	0	1 (0.2)
Pulmonary hypertension	0	1 (0.7)	0	1 (0.2)
Cerebral disorder	0	0	1 (0.7)	1 (0.2)
Pleural effusion	0	0	1 (0.7)	1 (0.2)
Salmonellosis	0	0	1 (0.7)	1 (0.2)

Table S2. Reasons for dose reductions, interruptions, and permanent discontinuations.

Reasons for dose reductions, interruptions, and permanent discontinuations	Long-term Duration of Benefit, ≥12 months (*n* = 225)	Intermediate Duration of Benefit, ≥6 mo and <12 months (*n* = 139)	Short-term Duration of Benefit, <6 months (*n* = 145)	Overall (*N* = 509)
Dose reduction of dab, n (%)	34 (15.1)	12 (8.6)	9 (6.2)	55 (10.8)
Reasons for dose reductions				
Adverse event	27 (79.4)	8 (66.7)	7 (77.8)	42 (76.4)
Physician decision	10 (29.4)	6 (50.0)	2 (22.2)	18 (32.7)
Technical problems	2 (5.9)	0	0	2 (3.6)
Dose reduction of tram, n (%)	19 (8.4)	10 (7.2)	2 (1.4)	31 (6.1)
Reasons for dose reductions				
Adverse event	16 (84.2)	6 (60.0)	1 (50.0)	23 (74.2)
Physician decision	3 (15.8)	4 (40.0)	1 (50.0)	8 (25.8)
Dosing error	0	1 (10.0)	0	1 (3.2)
Interruption of dab treatment, n (%)	65 (28.9)	35 (25.2)	34 (23.4)	134 (26.3)
Reasons for treatment interruptions				
Adverse event	61 (93.8)	30 (85.7)	28 (82.4)	119 (88.8)
Physician decision	11 (16.9)	2 (5.7)	0	13 (9.7)
Patient/guardian decision	4 (6.2)	1 (2.9)	0	5 (3.7)
As per protocol	2 (3.1)	0	0	2 (1.5)
Disease improvement under study	1 (1.5)	1 (2.9)	0	2 (1.5)
Interruption of tram treatment, n (%)	57 (25.3)	31 (22.3)	25 (17.2)	113 (22.2)
Reasons for treatment interruptions				
Adverse event	52 (91.2)	25 (80.6)	17 (68.0)	94 (83.2)
Physician decision	10 (17.5)	3 (9.7)	0	13 (11.5)
Patient/guardian decision	3 (5.3)	1 (3.2)	0	4 (3.5)
As per protocol	2 (3.5)	0	0	2 (1.8)
Disease improvement under study	1 (1.8)	1 (3.2)	0	2 (1.8)
Technical problems	1 (1.8)	0	0	1 (0.9)
Permanent discontinuation of dab, n (%)	142 (63.1)	134 (96.4)	144 (99.3)	420 (82.5)
Reasons for permanent discontinuations				
Progressive disease	105 (46.7)	95 (68.3)	105 (72.4)	305 (59.9)
Death	12 (5.3)	16 (11.5)	22 (15.2)	50 (9.8)
Adverse event	7 (3.1)	14 (10.1)	11 (7.6)	32 (6.3)
Physician decision	11 (4.9)	3 (2.2)	2 (1.4)	16 (3.1)
Patient/guardian decision	6 (2.7)	2 (1.4)	2 (1.4)	10 (2.0)
Study terminated by sponsor	0	3 (2.2)	0	3 (0.6)
Completed study	1 (0.4)	1 (0.7)	0	2 (0.4)

Reasons for dose reductions, interruptions, and permanent discontinuations	**Long-term Duration of Benefit, ≥12 months (*n* = 225)**	**Intermediate Duration of Benefit, ≥6 mo and <12 months (*n* = 139)**	**Short-term Duration of Benefit, <6 months (*n* = 145)**	**Overall (*N* = 509)**
Loss to follow-up	0	0	2 (1.4)	2 (0.4)
Permanent discontinuation of tram, n (%)	135 (60.0)	125 (89.9)	124 (85.5)	384 (75.4)
Reasons for permanent discontinuations				
Progressive disease	97 (43.1)	86 (61.9)	86 (59.3)	269 (52.8)
Death	12 (5.3)	16 (11.5)	22 (15.2)	50 (9.8)
Adverse event	9 (4.0)	12 (8.6)	11 (7.6)	32 (6.3)
Physician decision	9 (4.0)	4 (2.9)	1 (0.7)	14 (2.8)
Patient/guardian decision	6 (2.7)	3 (2.2)	2 (1.4)	11 (2.2)
Loss to follow-up	1 (0.4)	0	2 (1.4)	3 (0.6)
Study terminated by sponsor	0	3 (2.2)	0	3 (0.6)
Completed study	1 (0.4)	1 (0.7)	0	2 (0.4)

Abbreviations: dab, dabrafenib; tram, trametinib.

Note: A patient can have more than 1 dose reduction/treatment interruption; therefore, the percentages may sum to >100%.